Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Tumour And Target Volumes In Permanent Prostate Brachytherapy: A Supplement To The ESTRO/EAU/EORTC Recommendations On Prostate Brachytherapy.

C. Salembier, P. Lavagnini, P. Nickers, P. Mangili, A. Rijnders, A. Polo, J. Venselaar, P. Hoskin
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The aim of this paper is to supplement the GEC/ESTRO/EAU recommendations for permanent seed implantations in prostate cancer to develop consistency in target and volume definition for permanent seed prostate brachytherapy. Recommendations on target and organ at risk (OAR) definitions and dosimetry parameters to be reported on post implant planning are given.
This paper references
10.1088/0031-9155/48/9/306
Intraoperative dynamic dosimetry for prostate implants.
D. Todor (2003)
10.1016/S0022-5347(17)43003-5
Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate.
J. Oesterling (1987)
10.1016/S0360-3016(98)00372-1
Prostate seed implant quality assessment using MR and CT image fusion.
R. Amdur (1999)
10.1016/J.CLON.2005.07.003
Imaging for prostate cancer.
B. Carey (2005)
10.1016/S0360-3016(99)00282-5
Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
N. Yue (1999)
10.1016/J.IJROBP.2004.06.116
Results of a prospective multi-institutional phase II trial (RTOG 98–05) of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate
C. Lawton (2004)
10.1016/S0302-2838(02)00018-0
Importance of post-implant dosimetry in permanent prostate brachytherapy.
R. Stock (2002)
10.1016/J.BRACHY.2004.05.001
MRI-CT fusion to assess postbrachytherapy prostate volume and the effects of prolonged edema on dosimetry following transperineal interstitial permanent prostate brachytherapy.
J. Crook (2004)
10.1016/J.RADONC.2004.12.015
Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.
C. Haie‐Meder (2005)
10.1016/S0360-3016(03)01389-0
Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.
M. Rivard (2004)
10.1016/S0360-3016(00)00742-2
Optimizing target coverage by dosimetric feedback during prostate brachytherapy.
R. Cormack (2000)
10.1016/S0360-3016(02)02991-7
Comparison of MRI pulse sequences in defining prostate volume after permanent implantation.
P. McLaughlin (2002)
10.1118/1.598058
Source placement error for permanent implant of the prostate.
P. Roberson (1997)
10.1016/S0360-3016(00)00707-0
Postimplant dosimetry for 125I prostate implants: definitions and factors affecting outcome
R. Stock (2000)
10.1002/SIM.2257
A population model of prostate cancer incidence.
A. Tsodikov (2006)
10.1002/(sici)1097-0142(19990301)85:5<1204::aid-cncr34>3.3.co;2-o
Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
G. Hanks (1999)
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
J. Kirkpatrick (1998)
10.1200/JCO.2005.02.9751
The changing face of prostate cancer.
M. Cooperberg (2005)
10.1016/S0022-5347(17)42876-X
Morphometric and clinical studies on 68 consecutive radical prostatectomies.
T. Stamey (1988)
10.1097/00130404-200509000-00012
Permanent prostate brachytherapy (PPB) as it concerns seed migration and extraprostatic seed placement.
B. Davis (2005)
10.1016/J.BRACHY.2005.07.005
CT-ultrasound fusion prostate brachytherapy: a dynamic dosimetry feedback and improvement method. A report of 54 consecutive cases.
D. Fuller (2005)
10.1016/S0167-8140(01)00475-3
Impact of prostate volume evaluation by different observers on CT-based post-implant dosimetry.
B. Al-Qaisieh (2002)
10.1016/S0360-3016(99)00069-3
American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.
S. Nag (1999)
10.1016/S0360-3016(97)00501-4
Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging.
D. Dubois (1997)
10.1016/S0360-3016(99)00351-X
The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis.
S. Nag (2000)
Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: is extraprostatic seed placement necessary?
B. Davis (2000)
10.1016/J.BRACHY.2004.02.003
Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors.
D. Fuller (2004)
10.1016/S0360-3016(02)03754-9
Ultrasonography and fluoroscopic fusion for prostate brachytherapy dosimetry.
Lixin Gong (2002)
10.1097/01.JU.0000035544.25483.61
Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland.
G. Merrick (2003)
10.1118/1.598721
Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64.
Y. Yu (1999)
10.1016/J.RADONC.2005.11.014
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.
R. Poetter (2006)
10.1016/S0360-3016(99)00359-4
Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution.
W. R. Lee (2000)
10.1118/1.1576232
The effect of interobserver differences in post-implant prostate CT image interpretation on dosimetric parameters.
B. Han (2003)
10.1016/S0167-8140(00)00306-6
ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer.
D. Ash (2000)
10.1016/S0022-5347(05)66354-9
Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy.
R. Older (2001)
10.1016/J.RADONC.2004.09.004
GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.
G. Kovács (2005)
10.1016/S0360-3016(02)02950-4
Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy.
W. R. Lee (2002)
volume and the effects of prolonged edema on dosimetry following transperineal interstitial permanent prostate brachytherapy
J Crook (2004)
10.1016/S0360-3016(02)04142-1
Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy.
M. Zelefsky (2003)
10.1097/00130404-200503000-00010
Extraprostatic Seed Placement and Its Effect on Seed Loss
Elena A Nedea (2005)
10.1016/S0360-3016(98)00152-7
Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition.
F. Waterman (1998)
10.1016/J.IJROBP.2004.08.033
MR and CT image fusion for postimplant analysis in permanent prostate seed implants.
A. Polo (2004)
using a Mick applicator
P Lavagnini (2004)
10.1016/S0360-3016(97)00947-4
Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy.
B. Prestidge (1998)
10.1016/0360-3016(94)00599-G
Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy.
K. Wallner (1995)
10.1016/J.RADONC.2003.12.011
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation.
L. Potters (2004)
10.1016/S0360-3016(99)00405-8
Seed fixity in the prostate/periprostatic region following brachytherapy.
G. Merrick (2000)
10.1002/(SICI)1097-0142(19990615)85:12<2630::AID-CNCR20>3.0.CO;2-L
The radial distance of extraprostatic extension of prostate carcinoma
B. Davis (1999)
Trends in prostate cancer epidemiology in the year 2000.
A. Trinchieri (2005)
10.1016/J.RADONC.2004.10.016
The design and testing of a solid phantom for the verification of a commercial 3D seed reconstruction algorithm.
F. Siebert (2005)
10.1016/S0022-5347(01)65201-7
Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications.
Michael Cookson (1997)
10.1118/1.1568976
Prostate brachytherapy seed identification on post-implant TRUS images.
B. Han (2003)
10.1016/J.BRACHY.2005.01.002
Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
J. Crook (2005)
10.1016/S1538-4721(02)00014-4
Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy.
J. Crook (2002)
10.1016/J.BRACHY.2004.12.001
103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.
Jerrold Sharkey (2005)
10.1016/S0360-3016(99)00288-6
The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer.
M. Debois (1999)
10.1016/J.CANRAD.2004.06.001
Migration des grains d'iode 125 après curiethérapie prostatique : étude d'une série de 170 patients
L. Chauveinc (2004)
10.1002/1097-0142(19950115)75:2<530::AID-CNCR2820750216>3.0.CO;2-Y
Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens
P. A. Peller (1995)
10.1001/JAMA.1997.03540420041027
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
A. Partin (1997)
10.1016/J.BRACHY.2004.06.002
Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator.
C. Kunos (2004)
10.1118/1.597458
Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine.
R. Nath (1995)
[Iodin 125 seed migration after prostate brachytherapy: a study of 170 patients].
L. Chauveinc (2004)
10.1016/J.MRIC.2005.04.012
MR-guided interventions for prostate cancer.
E. Atalar (2005)
10.1016/J.RADONC.2004.02.006
Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes.
P. Mangili (2004)
10.1016/J.BRACHY.2004.12.002
Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants.
A. Haworth (2005)
The evaluation of radical prostatectomy specimens performed for carcinoma of the prostate. Therapeutic and prognostic implications
JI Epstein (1991)
10.1016/J.UROLONC.2004.09.002
Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: Extraprostatic seed placement correlates with migration
P. Carroll (2004)
10.1016/0360-3016(88)90448-8
Seed loss in interstitial radiotherapy of prostatic carcinoma with I-125.
H. Sommerkamp (1988)
Recommendations of the Braphyqs Prostate Sub-Group, the clinical part of the questionnaire
P Lavagnini (2005)
10.1016/S0022-5347(17)40079-6
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
A. Partin (1990)
10.1016/S0360-3016(01)01471-7
Standardization of prostate brachytherapy treatment plans.
R. Ove (2001)
10.1016/S0360-3016(01)01473-0
A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
L. Potters (2001)
10.1016/S0167-8140(02)00387-0
Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants.
E. Horwitz (2003)
10.1016/S0360-3016(02)02762-1
Effect of prostatic edema on CT-based postimplant dosimetry.
N. Dogan (2002)
10.1118/1.2012789
Examination of dosimetry accuracy as a function of seed detection rate in permanent prostate brachytherapy.
Yi Su (2005)
10.1300/J024v23n01_03
Methodology
M. Salah (2003)
: defining the organs at risk
AV D‘Amico (2005)
Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation.
G. Merrick (2000)
10.1118/1.1326448
Variability and accuracy of measurements of prostate brachytherapy seed position in vitro using three-dimensional ultrasound: an intra- and inter-observer study.
C. C. Blake (2000)
10.1118/1.598923
Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription.
J. Williamson (2000)
10.1016/S0360-3016(96)00618-9
Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants.
V. Narayana (1997)
10.1016/S0360-3016(96)00579-2
Cell kinetic measurements in prostate cancer.
K. Haustermans (1997)
Recommendations of the Braphyqs Prostate Sub-Group, the physics part of the questionnaire
P Mangili (2005)
10.1016/S1538-4721(03)00134-X
Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology.
L. Potters (2003)
10.1016/S0360-3016(96)00575-5
Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging.
M. Moerland (1997)
10.1118/1.1646040
Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.
M. Rivard (2004)
10.1016/S0360-3016(02)02755-4
Biologically effective dose for permanent prostate brachytherapy taking into account postimplant edema.
M. P. V. van Gellekom (2002)
10.1016/J.IJROBP.2003.12.003
Prostate cancer brachytherapy: is real-time ultrasound-based dosimetry predictive of subsequent CT-based dose distribution calculation? A study of 450 patients by the Institut Curie/Hospital Cochin (Paris) Group.
L. Chauveinc (2004)
10.1002/1097-0142(20000701)89:1<135::aid-cncr18>3.0.co;2
Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
H. Ragde (2000)
10.1016/S0022-5347(17)40761-0
Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer.
A. Partin (1989)
10.1016/S0022-5347(05)68574-6
Prostate brachytherapy: treatment strategies.
N. Stone (1999)
10.1016/J.RADONC.2006.04.009
Accuracy of seed reconstruction in prostate postplanning studied with a CT- and MRI-compatible phantom.
Marisol de Brabandere (2006)
10.1016/S0167-8140(02)00371-7
Pre- and post-implant dosimetry: an inter-comparison between UK prostate brachytherapy centres.
B. Al-Qaisieh (2003)



This paper is referenced by
10.15126/THESIS.00850347
New imaging techniques for brachytherapy
George Papachristodoulou (2019)
10.1111/j.1464-410X.2011.10825.x
Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer
S. Langley (2012)
10.1016/j.radonc.2013.01.007
Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study.
C. Melchert (2013)
10.1259/bjr.20130058
Technical and dosimetric aspects of iodine-125 seed reimplantation in suboptimal prostate implants.
L. Marcu (2013)
10.1016/j.radonc.2018.09.003
MRI-based automated detection of implanted low dose rate (LDR) brachytherapy seeds using quantitative susceptibility mapping (QSM) and unsupervised machine learning (ML).
R. Nosrati (2018)
10.1016/j.ijrobp.2010.06.009
Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
E. M. Roeloffzen (2011)
10.1016/J.FPUROL.2012.11.001
Peut-on traiter par curiethérapie en monothérapie par grains permanents les patients présentant un cancer de la prostate Gleason 7 ?
Luc Cormier (2013)
Salvage for radiorecurrent prostate cancer
M. Peters (2016)
10.1016/j.meddos.2016.07.001
Assessment of the feasibility of using transrectal ultrasound for postimplant dosimetry in low-dose-rate prostate brachytherapy.
R. Davies (2016)
10.1016/J.CANRAD.2016.07.038
Curiethérapie des cancers de la prostate
P. Pommier (2016)
10.1016/j.brachy.2016.03.012
Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.
N. J. Nasser (2016)
10.1007/978-3-642-36499-0_5
Patient Selection and Recommendations: HDR
G. Kovacs (2013)
10.1039/C4MD00416G
Recent discoveries and developments of androgen receptor based therapy for prostate cancer
Elancheran Ramakrishnan (2015)
10.1016/j.radonc.2012.01.016
Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients.
G. Goldner (2012)
10.1016/j.ajur.2019.02.001
The role of radiotherapy in localised and locally advanced prostate cancer
M. Bolla (2019)
10.1016/j.brachy.2016.04.330
Quantifying Iodine-125 Placement Accuracy In Prostate Brachytherapy Using Post-Implant Transrectal Ultrasound Images
M. Jamaluddin (2017)
10.1111/1754-9485.12413
Which patients benefit from post‐implant CT dosimetry after real‐time intraoperative planning for low dose rate prostate brachytherapy? Case series and systematic literature review
N. Mitina (2016)
10.5114/jcb.2016.60452
Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature
H. Kunogi (2016)
10.1016/j.radonc.2008.11.005
Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer--a matched-pair comparison.
M. Pinkawa (2009)
10.1007/s00066-008-1886-3
Seed Displacements after Permanent Brachytherapy for Prostate Cancer in Dependence on the Prostate Level
M. Pinkawa (2008)
10.1088/0031-9155/53/20/004
Variation in target and rectum dose due to prostate deformation: an assessment by repeated MR imaging and treatment planning.
E. Kerkhof (2008)
10.1186/1748-717X-9-93
Influence of body mass index and periprostatic fat on rectal dosimetry in permanent seed prostate brachytherapy
D. Tiberi (2014)
10.1016/j.brachy.2015.10.004
Rectal dose constraints for salvage iodine-125 prostate brachytherapy.
M. Peters (2016)
10.1007/978-3-319-23464-9_14
Radiation Therapy: Brachytherapy
B. Cox (2016)
Low-dose rate brachytherapy of the prostate in elderly patients Brachiterapia prostatica low-dose rate nel paziente anziano C. ChiumentoA. FiorentinoR. CaivanoS. ClementeV. Fusco
Costanza Chiumento (2013)
10.1177/1179554917738765
Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes
F. Barbera (2017)
10.1016/S1761-3310(16)77897-2
Técnicas de braquiterapia por cáncer de próstata
L. Cormier (2016)
10.1016/J.RADONC.2007.09.018
The value of Day 1 imaging following LDR prostate brachytherapy.
J. Nobes (2008)
Stepping source prostate brachytherapy: From target definition to dose delivery
Anna M. Dinkla (2015)
10.1007/s00092-014-0001-6
Permanente LDR-Brachytherapie und alternative Verfahren
Jörg Zimmermann (2014)
10.1007/978-3-319-49911-6_27
Focal Brachytherapy and Intensity-Modulated Radiation Therapy
Richard A. Hsi (2017)
10.21873/invivo.11710
A Population-based Statistical Model for Investigating Heterogeneous Intraprostatic Sensitivity to Radiation Toxicity After 125I Seed Implantation
K. Kobayashi (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar